Literature DB >> 8140628

Erythrocytosis after renal transplantation. The response to theophylline treatment.

Y Ilan1, M Dranitzki-Elhallel, D Rubinger, J Silver, M M Popovtzer.   

Abstract

Erythrocytosis was found in 20 out of 127 patients who underwent renal transplantation (15.7%). Four were found to have elevated erythropoietin concentrations (139.7 +/- 22.0 microns/ml) and 7 had normal levels (52.3 +/- 84 microns/ml (normal -60). The growth of erythroid CFUs was found to be normal in all patients. Theophylline treatment was given to 11 patients. The patients were divided into 3 groups according to their response: (1) patients with high erythropoietin levels whose hematocrit decreased from 59.6% to 46.3% within 2 weeks of treatment in parallel with a fall in erythropoietin; (2) patients with normal erythropoietin levels in whom theophylline therapy reduced the hematocrit from 58.7% to 47.2%; and (3) patients in whom theophylline had no effect on their erythrocytosis. We conclude that erythrocytosis after renal transplantation is a heterogenous condition and that several mechanisms are involved. In some patients, high erythropoietin levels or high sensitivity to erythropoietin are associated with the erythrocytosis. Theophylline therapy is beneficial in more than 50% of the cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140628     DOI: 10.1097/00007890-199403150-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.

Authors:  T Yagisawa; H Toma; H Yaguchi; M Tomaru; Y Iijima; H Suzuki; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Theophylline treatment may adversely affect the anoxia-induced erythropoietic response without suppressing erythropoietin production.

Authors:  Argirios E Tsantes; Stergios T Tassiopoulos; Stefanos I Papadhimitriou; Stefanos Bonovas; Nikolaos Poulakis; Athina Vlachou; Kalitsa Filioussi; Dimitrios Loukopoulos
Journal:  Eur J Clin Pharmacol       Date:  2003-08-05       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.